GLP - 1 obesity drugs

Search documents
Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock
Benzinga· 2025-06-13 14:47
Eli Lilly & Co. LLY may be down over 8% in the past month and nearly 5% over the past five days, but JPMorgan analyst Chris Schott isn't backing off. In fact, he's doubling down.Zepbound's Momentum Keeps Eli Lilly In The LeadWith Zepbound continuing to dominate the GLP-1 obesity category and new catalysts on the horizon, JPMorgan sees Eli Lilly as still one of the top picks in the sector.Prescriptions for both Zepbound and Mounjaro are running ahead of expectations in the second quarter, positioning Eli Lil ...
Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit
CNBC· 2025-05-02 05:19
A view of the sign and logo of the Roche Holding AG headquarters on April 11, 2025 in Basel, Switzerland. Sedat Suna | Getty Images News | Getty ImagesCOPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight loss candidate.The deal, announced in March and set to close in the second quarter, marks the Swiss pharma's latest bid to compete with weight loss heavyweights Novo Nordis ...